Category: Stock Market

Now could be the time to buy Cyclopharm Ltd (ASX: CYC) shares.

That’s the view of analysts at Bell Potter, who believe this small-cap ASX share could deliver market-beating returns over the next 12 months.

What is Cyclopharm?

It is a medical device company operating in nuclear medicine.

Bell Potter notes that Cyclopharm’s main revenue driver is Technegas, which is a system indicated for functional lung imaging.

The primary use of Technegas is diagnosis of pulmonary embolism in patients contraindicated for a CT scan. It was approved for use in the United States in September 2023.

Bell Potter was pleased with the small-cap ASX share’s annual general meeting update. It points out that management remains bullish on the remainder of 2026 and beyond. It said:

The AGM commentary maintains the bullish outlook for the remainder of CY26 and beyond. The CEO re-affirmed guidance for 250 – 300 Technegas generators installed in the US by the end of 31 Dec 2026. There are currently 55 generators in market, hence 195 instals required to meet the bottom end of guidance. We estimate 11 instals in the first 17 weeks of CY26 including 5 since 31 March.

Bell Potter also highlights that the small-cap ASX share has a sizeable pipeline with a high conversion probability. The broker adds:

CYC has 175 contracts signed and awaiting installation with a further 111 at contract review stage and described as a very high conversion probability. Beyond these, the pipeline is extensive with several hundred devices at the proposal stage. Numerous hospital groups have now committed to subsequent devices across locations in their networks, in fact, half the growth (we presume in FY26) is attributable to 2nd and subsequent orders by existing clients. We conclude that the signs are highly encouraging for strong revenue growth in FY26.

~9 weeks remain in the half, hence CYC is on track to hit our forecast of 65 instals in the US by 30 June. The bottom end of the guidance requires an enormous acceleration of installations in 2H, however, with contracts in place the business is there to be had. The client service teams are now engaged with multiple installation programs at any one time to ensure a continuous stream of instals on a weekly basis.

Small-cap ASX share tipped to rise

According to the note, the broker has retained its buy rating and $1.00 price target on Cyclopharm’s shares.

Based on its current share price of 84.5 cents, this implies potential upside of 18% for investors over the next 12 months.

Commenting on its buy recommendation, the broker said:

The revenue base to CYC from 250 devices in the US is estimated at ~A$23m annual recurring revenue. We expect cash burn has now peaked and will begin to fall in 2H26. Next major catalyst is the June quarter update where we are increasingly confident that the pace of generator installations in the US will be sustained at the current rate or better. No earnings adjustments, PT remains $1.00.

The post Which small-cap ASX share could beat the market over the next 12 months? appeared first on The Motley Fool Australia.

More reading

• Down 26% year to date, is it time to buy low on this ASX small-cap?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

I’d describe Sigma Healthcare Ltd (ASX: SIG) as one of Australia’s top shares because of the growth it’s currently achieving and its potential to continue growing at a very attractive rate.

When I look at non-tech names that could deliver the most profit growth over the next five years, I think Sigma Healthcare – the owner of the Chemist Warehouse brand – is one of the most compelling businesses on the ASX.

At the time of writing, the Sigma Healthcare share price is down by approximately 10% from its 2026 high in February 2026. That’s not a huge fall, but it has big growth plans so it may be rare for it to be this low again.

I think this is a good time to look at the business, given it’s cheaper and looks more compelling than ever.

Excellent Australian growth

When I think about which businesses are likely to deliver market-beating returns (of more than 10% per year), I think it’s a really big help if the business is achieving revenue growth of at least 10% per year. At that pace, I’d call it one of Australia’s top shares as long as it’s combined with profit growth.

In my view, revenue is one of the biggest drivers of net profit, perhaps the most important one because of how that feeds into a company’s other profit lines.

Considering the business is already worth tens of billions of dollars, it’d be understandable for the growth rate to be fairly slow these days. But, Chemist Warehouse is still growing its market share at a very strong pace.

The business recently gave a trading update which included some very positive numbers.

The Chemist Warehouse-branded Australian store network saw total sales growth of 16.7% for the period of 1 July 2025 to 30 April 2026. This isn’t just being driven by new stores – it reported that like-for-like (LFL) growth was 14.4%, showing excellent growth at its existing stores.

These sales were strong despite cycling the structural uplift of GLP-1 sales in the second half of FY25. Growth in GLP-1 sales growth is expected to continue.

International growth

The most important thing is that the core business is growing well, but Chemist Warehouse has another massive growth pillar to its company – international. This is one of the main reasons why I think it’s one of Australia’s top shares.

It currently has a presence in New Zealand, Ireland, Dubai and China. While the sales generated by these markets are just a fraction of what Australia delivers, there is scope for the international segment to become a bigger part of the picture, considering Australia’s population is relatively small.

According to the recent trading update, Chemist Warehouse’s international store network delivered total sales growth of 24.7%, with like-for-like sales growth of 11.8%.

It also recently announced an acquisition agreement that will allow it to expand into the UK, initially starting with a few locations in London. The UK has a bigger population than Australia, so if Chemist Warehouse can get this right then the opportunity is large for that market.

Rising profit margins

Many investors value a business based on how much profit it generates and could generate in the future.

As I’ve said, revenue is already growing at a fast pace. But, excitingly, the company’s net profit can grow even faster than that because of its rising profit margins. That’s another sign that it’s one of Australia’s top shares, in my view.

In the FY26 half-year result, total revenue increased 14.9% to $5.5 billion, normalised operating profit (EBIT) grew 18.7% to $582.9 million and normalised net profit after tax (NPAT) rose 19.2%. As you can see, each line of the financials grew faster than the last.

If operating leverage continues to play out and its bottom line continues rising at a strong pace, it’ll definitely be one to watch. I’m planning to buy some of this business this year, which I’m happy to call one of Australia’s top shares.

The post A rare buying opportunity in 1 of Australia’s top shares? appeared first on The Motley Fool Australia.

More reading

• 5 ASX 200 shares downgraded by experts this week
• What is Morgans saying about Flight Centre, Sigma, and Westpac shares?
• 2 top ASX shares to buy and hold for the next decade
• Here are the top 10 ASX 200 shares today
• Why Flight Centre, Sigma Healthcare, Vault Minerals, and WiseTech shares are storming higher today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Cochlear Ltd (ASX: COH) shares have gone into freefall in 2026 after a brutal earnings downgrade stunned investors.

The ASX healthcare stock is down roughly 62% year to date, wiping billions from its market value and leaving many shareholders nursing heavy losses.

Things look even worse for investors who bought near the peak.

Damage is real

Back in late July last year, Cochlear shares were trading just below $320. At the time of writing, they have crashed to $99.89.

That represents a staggering decline of almost 69% in just nine months.

For investors, the damage is very real.

A $10,000 investment at $319.50 per share would have bought roughly 31 Cochlear shares in July. Today, those same shares would be worth approximately $3,126.

That’s a painful capital loss of more than $6,870 in a very short time.

What triggered the collapse?

The sell-off accelerated after Cochlear released a disappointing trading update on 22 April.

Cohlear shares plunged from around $168 to near $90 within days — an extraordinary 46% wipeout for a blue-chip healthcare company.

Although the share price has since recovered slightly, the broader damage remains significant.

Cochlear, which controls roughly 50% of the global cochlear implant market, sharply downgraded its FY26 underlying net profit guidance to between $290 million and $330 million.

That was a major cut from its previous guidance range of $435 million to $460 million. For a company long viewed as one of the ASX’s most reliable healthcare performers, the downgrade rattled confidence badly.

Management of the ASX healthcare stock pointed to weaker demand across key developed markets, with fewer hearing implant procedures taking place than expected. The company also flagged disruptions in the Middle East, where ongoing conflict has contributed to cancelled orders and delayed deliveries.

At the same time, some patients appear to be postponing surgeries, with referrals slowing and procedures being pushed back.

Is this temporary?

Importantly, the long-term investment case may not be broken.

Cochlear remains the global leader in implantable hearing technology and continues investing heavily in research and development, reinvesting around 13% of revenue into innovation.

Cochlear shares also continue benefiting from a large and growing pool of patients with hearing loss, particularly as populations age globally. Management still believes there is a “significant, unmet and addressable clinical need” supporting long-term growth.

That suggests the current weakness could be more cyclical than structural.

Analysts remain divided

Even so, uncertainty remains high.

At current prices, Cochlear shares are trading on a little over 19 times FY26 earnings, a valuation level rarely seen for a company previously considered a premium healthcare stock.

That has divided broker opinion sharply. Jarden currently has a $169 price target on Cochlear shares, implying potential upside of almost 70% if conditions improve.

On the other hand, Macquarie has slashed its valuation target from $239 to $115.

Morgans sits somewhere in the middle, maintaining a hold rating and a $107.17 target price.

For now, the sharp divergence in analyst forecasts highlights just how uncertain Cochlear’s near-term outlook has become.

The post $10,000 invested in Cochlear shares in July is now worth… appeared first on The Motley Fool Australia.

More reading

• Is this ASX healthcare share a buy for its 6.2% dividend yield?
• Money to invest? I’d follow Warren Buffett to get rich
• 3 cheap ASX shares for value investors to buy today
• Here are the top 10 ASX 200 shares today
• The Aussie dollar just hit a 4-year high. Which ASX shares will benefit?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Australian household spending fell for the first time in over a year in February 2026.

The RBA, in its May Statement on Monetary Policy, also alluded to this drop in consumer spending:

The response on consumption to lower real household incomes is assumed to be faster than the typical historical experience, given the share declines we have seen in consumer sentiment.

With this somewhat gloomy backdrop, it’s time to assess what the implications could be for some beloved Aussie stocks.

Coles Group Ltd (ASX: COL)

Coles is the most defensive name on this list, given its focus on supermarket retail.

As one of Australia’s largest supermarkets, Coles benefits from defensive consumer spending. After all, consumers will always need to eat regardless of the prevailing economic conditions.

90% of Coles’ revenue comes from its supermarket business, which may help protect it from a major economic slowdown.

However, Coles remains exposed to reduced consumer spending, which can negatively affect margins.

What’s more, the ACCC’s ongoing court case alleging illusory Down Down discounts, set to be resolved in May 2026, has increased regulatory risks, and Coles reported lower profit in its first half of fiscal 2026 despite higher sales revenue.

A sustained consumer pullback could further erode margins and profitability, leaving Coles uniquely exposed to any noticeable decline in consumer spending.

Woolworths Group Ltd (ASX: WOW)

One key difference between Woolworths and Coles is Woolworths’ ownership of BIG W.

BIG W meaningfully increases Woolworths’ exposure to consumer spending habits outside of supermarket retail.

In 2025, the unit posted an EBIT loss of $63 million, squeezed by clearance activity, soft discretionary spending, and operational complexity.

More recently, Bell Potter downgraded Woolworths shares to hold with a reduced price target of $35.50 (from $38.25), citing supply chain cost pressures.

Reduced consumer spending within this unit may lead to even more pain for Woolworths in the short-to-medium term.

Qantas Airways Ltd (ASX: QAN)

Australians tend to cut holidays and flights first when mortgage repayments bite.

Qantas, as Australia’s flag carrier, is on the frontline of this reduced spending.

Analysts identify an economic downturn as a key risk that could cause corporate clients to cut travel budgets, directly hitting Qantas’ most profitable customer base.

What’s more, jet fuel costs have more than doubled since February 2026, which is set to hit Qantas earnings directly.

Qantas’ loyalty program and domestic duopoly may provide some buffer, but be ready for Qantas’ earnings to potentially be hit by macroeconomic issues.

Foolish Takeaway

None of these companies is in crisis, but they are exposed to a sustained drop-off in consumer spending.

Investors may want to consider diversifying into companies that service businesses or governments with sticky long-term contracts.

In the meantime, investors would do well to keep a close eye on discretionary spending data in the months ahead.

The post 3 ASX retail shares exposed to a drop in consumer spending appeared first on The Motley Fool Australia.

More reading

• Down 17% since February, why Qantas shares are looking like a bargain buy
• Money to invest? I’d follow Warren Buffett to get rich
• How to build a $1,000 a month passive income from the ASX
• 5 ASX 200 shares downgraded by experts this week
• How much passive income could I make with $10,000 in Qantas shares?

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Woolworths Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Dyno Nobel Ltd (ASX: DNL) share price was in focus on Monday after the company reaffirmed its full-year earnings guidance, highlighting robust underlying growth in its global explosives business and a sharp lift in first-half earnings.

What did Dyno Nobel report?

• Statutory net profit after tax (NPAT): $20 million (1H25: $7 million)
• NPAT excluding individually material items (IMIs): $161 million, up 83% (1H25: $88 million)
• EBIT excluding IMIs: $243 million, up 39% (1H25: $174 million)
• EBITDA excluding IMIs: $378 million, up 17% (1H25: $323 million)
• Interim dividend: 4.6 cents per share (unfranked), 50% payout ratio
• Return on Invested Capital: 9.5% (1H25: 6.1%)

What else do investors need to know?

Dyno Nobel completed the strategic separation of its Fertilisers business during the first half, signing a binding agreement for the sale of the Phosphate Hill facility. This move positions the company clearly as a standalone explosives business, aligning with its long-term growth and sustainability strategy.

In terms of capital management, $558 million of the $900 million on-market share buyback program has been completed, and the buyback is set to resume following the trading blackout ending. The company also reported improved financial metrics, including stronger interest cover (12.5x) and a net debt to EBITDA ratio of 1.3x, comfortably within policy limits.

What did Dyno Nobel management say?

CEO and Managing Director Mauro Neves commented:

“1H26 marks the beginning of a new era for Dyno Nobel as we concluded our separation from the Fertilisers business and move forward as a pureplay global explosives leader. We continued the successful execution of our transformation program, and our explosives business delivered robust underlying earnings growth, driven by the strong operating performance of our privileged assets.

Safety always remains our number one priority, and while I’m disappointed to record an increase in our total recordable injury frequency rate, no incidents were classified as serious harm and we saw an overall reduction in injury severity. We will continue our focus on field leadership and proactive hazard identification, with targeted explosives risk reviews at our key manufacturing facilities.

Highlighting the resilience of our business in the volatile global landscape, I am pleased to report we remain on track to deliver both our FY26 EBIT guidance of $460m – $500m and our FY28 EBIT ambition of $600m as our transformation program continues to yield results.

Looking ahead, our gas backed manufacturing facilities, high vertical integration and consistent earnings growth with low volatility position Dyno Nobel as an increasingly compelling investment proposition.”

What’s next for Dyno Nobel?

Dyno Nobel has reaffirmed its FY26 EBIT guidance for the explosives business at $460 million to $500 million, with its transformation program progressing as planned. The group now expects lower capital expenditure in the $250 million to $300 million range for FY26, as some growth investment shifts into FY27.

The successful sale of the Fertilisers business reduces operational and environmental commitments, reinforcing Dyno Nobel’s focus on global explosives and blasting services. Management expects to benefit from stable, vertically integrated operations and continued momentum from its transformation program.

Dyno Nobel share price snapshot

Over the past 12 months, Dyno Nobel shares have risen 27%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Dyno Nobel posts higher earnings as explosives transformation accelerates appeared first on The Motley Fool Australia.

More reading

• Inghams Group boosts FY26 guidance as poultry volumes and prices rise
• Metcash shares: FY26 earnings highlight portfolio resilience and cost discipline
• CSL cuts FY26 guidance, flags $5bn in impairments
• Is this the best ASX 200 stock to buy in May?
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Inghams Group Ltd (ASX: ING) share price is in focus today after the company reaffirmed its FY26 EBITDA guidance and reported higher group poultry volumes and selling prices for the first nine months of the year.

What did Inghams Group report?

• Reaffirmed FY26 guidance for Underlying EBITDA (pre AASB 16) of $180 million to $200 million
• For the first nine months of FY26, group core poultry volumes rose 1.1% versus prior comparable period (PCP)
• Group core poultry net selling prices increased 1.1% versus PCP
• Annualised cost savings initiatives expected to deliver $60–80 million
• Revised capital expenditure guidance of approximately $80 million for FY26

What else do investors need to know?

Inghams continues to make operational improvements, with stronger performance reported in areas such as yield, labour, and inventory management. The company reduced its frozen inventory by $25 million, which has helped restore system balance and improve cash flows.

Cost pressures remain a focus, particularly feed, diesel fuel, and packaging. The company noted a net $7–10 million impact expected from higher fuel costs in FY26, partially offset by pricing actions and efficiency gains. Feed costs are presently well covered for the year, though higher costs are expected in FY27.

What did Inghams Group management say?

Chief Executive Officer and Managing Director said Ed Alexander said:

We are seeing improved operational performance and positive momentum from initiatives already delivered, while reaffirming our FY26 guidance in a challenging environment.

What’s next for Inghams Group?

Inghams says it will maintain its focus on stabilising the business, optimising assets, and growing value per bird. The company’s ongoing operational improvements and cost controls are expected to support further earnings and return growth, even as it navigates uncertainties in input costs.

Growth priorities include expanding ingredients and higher value product segments, leveraging recent investments, and scaling new business initiatives like launching the Bostocks brand in Australia.

Inghams Group share price snapshot

Over the past 12 months, Inghams Group shares have declined 55%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Inghams Group boosts FY26 guidance as poultry volumes and prices rise appeared first on The Motley Fool Australia.

More reading

• Dyno Nobel posts higher earnings as explosives transformation accelerates
• Metcash shares: FY26 earnings highlight portfolio resilience and cost discipline
• CSL cuts FY26 guidance, flags $5bn in impairments
• Is this the best ASX 200 stock to buy in May?
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Metcash Ltd (ASX: MTS) share price is in focus today after the company announced an underlying profit after tax of $268–270 million for FY26, supported by revenue growth of 0.7% and resilient performances across Food, Liquor, and Hardware.

What did Metcash report?

• Underlying NPAT expected at $268–270 million
• Group revenue up 0.7% year-on-year (+3.8% excluding tobacco)
• Liquor EBIT margin recovered in the second half
• Hardware & Tools revenue rose 4.3%, with improved sales momentum
• Strong cashflow and disciplined capital expenditure, at ~$170 million (about $30 million below guidance)
• Ongoing cost initiatives targeting at least ~$25 million annualised savings in FY27

What else do investors need to know?

Metcash’s Food segment saw supermarkets remain competitive, helped by promotional programs like Extra Specials, while Foodservice & Convenience grew strongly on the back of new customer wins. The group’s Liquor division continued to gain market share, fuelled by a multi-channel approach and a return to long-term EBIT margins in the second half.

Despite challenging conditions in the Trade market, the Hardware & Tools business improved its sales momentum in the latter half, benefiting from pricing and range initiatives. Cash realisation outperformed targets, helping keep the company’s debt leverage at the lower end of its guided range.

What did Metcash management say?

Metcash Group CEO Doug Jones said:

We have delivered a solid result supported by the resilience of our Food and Liquor businesses, our diversified portfolio and disciplined execution.

Hardware & Tools maintained share in a soft Trade market, with improved second half sales momentum. We have taken further action to strengthen the business and position the Group for sustained performance.

Cashflow remained strong, with cash realisation above guidance and leverage at the low end of our target range.

What’s next for Metcash?

Looking ahead, Metcash is focusing on structural cost reductions, with new programs projected to yield at least $25 million in annual savings by FY27. These efforts target labour and non-trade procurement savings and are set to further support profit margins, particularly in Hardware & Tools.

The company is also closely monitoring global uncertainties—like those affecting freight and product supply—by maintaining higher inventory levels as a precaution. Management continues to proactively support customers and prioritise efficient operations in a changing market.

Metcash share price snapshot

Over the past 12 months, Metcash shares have declined 18%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Metcash shares: FY26 earnings highlight portfolio resilience and cost discipline appeared first on The Motley Fool Australia.

More reading

• Dyno Nobel posts higher earnings as explosives transformation accelerates
• Inghams Group boosts FY26 guidance as poultry volumes and prices rise
• CSL cuts FY26 guidance, flags $5bn in impairments
• Is this the best ASX 200 stock to buy in May?
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The CSL Ltd (ASX: CSL) share price is in focus today after the company delivered a 90-day interim CEO review and financial update, revealing revised, lower FY26 earnings guidance and plans for around $5 billion in additional asset impairments.

What did CSL report?

• FY26 revenue expected to be around $15.2 billion (constant currency).
• FY26 NPATA (excluding restructuring costs and impairments) forecast at approximately $3.1 billion.
• Additional non-cash, pre-tax asset impairments of around $5 billion expected across FY26 and FY27, mostly relating to CSL Vifor intangibles and under-used assets.
• US Immunoglobulin revenue to take a $300 million impact due to inventory normalisation.
• Albumin in China revenue down by $200 million from market value decline, despite increases in volume and market share.
• Other headwinds, including Middle East conflict and product competition, expected to weigh by about $150 million.

What else do investors need to know?

CSL says its core business in plasma collection and influenza vaccines remains strong, with ongoing demand growth in key markets. The transformation and efficiency program continues, targeting $500–$550 million in annual savings by FY28 as the business works to simplify operations and focus capital on value-adding growth.

While US Immunoglobulin and Albumin product segments are both seeing stable or rising demand, short-term revenue has been impacted by price pressure and changes in market dynamics. CSL Seqirus is tracking moderately ahead of earlier forecasts for the year.

Leadership changes are also underway, with a global search for a permanent CEO progressing and commercial leadership transitioning to Diego Sacristan from 1 July 2026.

What did CSL management say?

Interim Chief Executive Officer and Managing Director Gordon Naylor said:

Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise. As a result, we have now revised down our 2026 financial year guidance. CSL’s culture and people continue to be first class, the industry is stable and growing and the company has evident strengths in plasma collections and influenza vaccines. I am confident that the company can be returned to profitable growth and my work is to position the business and the next CEO for success.

What’s next for CSL?

CSL expects to see revenue growth in its CSL Behring division in the second half of FY26, underpinned by commercial execution and its cost transformation initiatives. Seqirus is also anticipated to outperform previous forecasts.

Management is focused on driving sustainable value through portfolio growth, operational efficiencies, and disciplined capital allocation. The company is streamlining the organisation and accelerating its transformation program. A further update will be provided with CSL’s full-year results in August 2026.

CSL share price snapshot

Over the past 12 months, CSL shares have declined 49%, trailing the S&P/ASX 200 Index (ASX: XJO) which had risen 6% over the same period.

View Original Announcement

The post CSL cuts FY26 guidance, flags $5bn in impairments appeared first on The Motley Fool Australia.

More reading

• Dyno Nobel posts higher earnings as explosives transformation accelerates
• Inghams Group boosts FY26 guidance as poultry volumes and prices rise
• Metcash shares: FY26 earnings highlight portfolio resilience and cost discipline
• Is this the best ASX 200 stock to buy in May?
• Why I’d buy CSL shares at their 52-week low

Motley Fool contributor Laura Stewart has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

ASX healthcare shares have endured a brutal run in 2026, making the sector one of the market’s weakest performers this year.

At the time of writing, shares in ResMed Inc (ASX: RMD) are down 21% this year, while Mesoblast Ltd (ASX: MSB) has fallen 26%. Meanwhile, Pro Medicus Ltd (ASX: PME) has slumped an even steeper 41%.

The sector is facing several major headwinds. Currency pressures, rising labour costs, and uncertainty around potential US tariffs have all weighed on investor sentiment, particularly for companies with large offshore operations.

The weakness has become so widespread that the S&P/ASX 200 Health Care Index (ASX: XHJ) is at an 8-year low, with many ASX healthcare shares trading near 52-week lows.

But while sentiment remains fragile, some brokers believe the sector-wide sell-off has created compelling buying opportunities for long-term investors.

ResMed: Steady earnings growth

ResMed remains one of the ASX’s largest and most established healthcare companies, specialising in sleep apnoea treatment and respiratory care devices.

The company benefits from strong recurring revenue streams, global market leadership, and growing long-term demand driven by ageing populations and increasing awareness of sleep disorders.

However, ResMed still faces challenges. Currency movements can impact earnings translation, while ongoing cost pressures and uncertainty around US healthcare policy remain key risks.

Despite this, analysts still see meaningful upside ahead. Morgans currently has an add rating and a $41.72 price target on the ASX healthcare share. That implies potential upside of around 46% from current levels.

If ResMed can continue delivering steady earnings growth while healthcare sentiment improves, the recent share price weakness could prove temporary.

Mesoblast: Elevated risks

Mesoblast is one of the ASX’s most speculative healthcare shares, but it also offers potentially enormous upside if its cell therapy treatments continue progressing commercially.

Investor interest in Mesoblast has largely centred around its regenerative medicine pipeline and opportunities in inflammatory disease treatment.

Biotech investing always carries elevated risks, particularly around regulatory approvals, commercial execution, and funding requirements. Share price volatility can also be extreme.

Even so, some brokers remain highly optimistic. Bell Potter recently reaffirmed its speculative buy rating on Mesoblast shares and maintained a $4.45 price target on the company. That target suggests the stock could more than double over the next year if momentum improves and clinical progress continues.

For investors comfortable with higher risk, Mesoblast may offer significant upside leverage to positive developments.

Pro Medicus: Valuation concerns

Pro Medicus has long been considered one of the ASX’s premier healthcare technology companies thanks to its globally respected medical imaging software platform.

The company has built a strong reputation for securing major hospital contracts in the US and delivering high-margin recurring revenue growth.

However, the Pro Medicus share price has deteriorated sharply in recent months as broader healthcare weakness and valuation concerns hit investor confidence.

Despite the sell-off, some analysts still remain bullish on the company’s long-term outlook. Morgan Stanley currently maintains a buy rating on Pro Medicus shares with a 12-month price target of $200. That valuation implies potential upside of roughly 55% from current levels.

For investors seeking exposure to healthcare technology and long-term structural growth, Pro Medicus may now look far more attractive after its substantial decline.

The post 3 ASX healthcare shares to buy while they’re on sale appeared first on The Motley Fool Australia.

More reading

• Top brokers name 3 ASX shares to buy next week
• How I’d invest $5,000 across ASX tech stocks
• Money to invest? I’d follow Warren Buffett to get rich
• 3 of the best Aussie ASX growth shares to buy and hold until 2036
• 3 reasons to buy this $42 billion ASX healthcare share

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Xero Ltd (ASX: XRO) share price has been one of the hardest hit on the ASX within the past year. It’s down 57% from 24 June 2025, as the chart below shows.

Xero is one of the largest cloud accounting software businesses in the world, with a sizeable market position in a number of countries including Australia, New Zealand, the UK, South Africa, the USA, Singapore and plenty more.

The ASX tech share has suffered due to market concern about what impact AI could have on software companies. But, some experts believe the Xero share price could be ready to recover significant ground in the months ahead. Let’s take a look at the predictions.

Expert projections about the Xero share price

According to CMC Invest, there are multiple analysts that currently think the ASX tech share is an attractive buy.

Of the analysts that CMC Invest tracks, there have been six buy ratings and one hold rating in the last three months.

The average price target across those seven ratings is $121.78, which implies a possible rise of around 45% in the year ahead.

The most optimistic price target on the Xero share price is $165. If that happened over the next year, it’d be a rise of 97%. However, the most pessimistic price target is $86.80, suggesting a small rise over the next year.

Price targets are not guarantees of what’s going to happen, of course.

The main thing that could help justify a higher Xero share price is delivering ongoing earnings growth.

Strong earnings growth

The latest result from the business was the FY26 half-year result.

Subscribers increased by 10% to 4.6 million, showing the ongoing global success of attracting more customers who want its efficiency and time-saving tools. The company also achieved a 15% increase in the average revenue per user (ARPU) to $49.63, which was significantly assisted by price increases.

The above factors helped the business achieve 20% operating revenue growth to NZ$1.19 billion, operating profit (EBITDA) rose 21% to NZ$378 million, net profit after tax (NPAT) jumped 42% to NZ$135 million and free cash flow soared 54% to NZ$321 million.

We can’t know for sure what Xero’s FY27 profit growth will be, but if it continues growing at a strong double-digit rate, then it will help give investors confidence that it will be unaffected in this AI era.

The post How much could the Xero share price rise in the next year? appeared first on The Motley Fool Australia.

More reading

• Money to invest? I’d follow Warren Buffett to get rich
• $10,000 invested in Xero shares 3 weeks ago is now worth…
• 3 ASX 200 shares on my May watchlist
• Forget gold! Start hunting fallen ASX 200 shares to buy for an earlier retirement
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.